ALT vs. FULC, ABUS, KMDA, MGTA, CTIC, CPRX, RCKT, ZLAB, GLPG, and KROS
Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Fulcrum Therapeutics (FULC), Arbutus Biopharma (ABUS), Kamada (KMDA), Magenta Therapeutics (MGTA), CTI BioPharma (CTIC), Catalyst Pharmaceuticals (CPRX), Rocket Pharmaceuticals (RCKT), Zai Lab (ZLAB), Galapagos (GLPG), and Keros Therapeutics (KROS). These companies are all part of the "medical" sector.
Fulcrum Therapeutics (NASDAQ:FULC) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership.
In the previous week, Altimmune had 4 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 13 mentions for Altimmune and 9 mentions for Fulcrum Therapeutics. Altimmune's average media sentiment score of 0.95 beat Fulcrum Therapeutics' score of 0.61 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.
Fulcrum Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.
Fulcrum Therapeutics has a net margin of -3,470.05% compared to Fulcrum Therapeutics' net margin of -22,645.37%. Altimmune's return on equity of -40.60% beat Fulcrum Therapeutics' return on equity.
Altimmune has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.
89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 4.1% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Fulcrum Therapeutics presently has a consensus price target of $15.57, suggesting a potential upside of 101.18%. Altimmune has a consensus price target of $17.25, suggesting a potential upside of 147.49%. Given Fulcrum Therapeutics' higher possible upside, analysts plainly believe Altimmune is more favorable than Fulcrum Therapeutics.
Fulcrum Therapeutics received 47 more outperform votes than Altimmune when rated by MarketBeat users. However, 70.00% of users gave Altimmune an outperform vote while only 64.86% of users gave Fulcrum Therapeutics an outperform vote.
Summary
Fulcrum Therapeutics beats Altimmune on 10 of the 17 factors compared between the two stocks.
Get Altimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altimmune Competitors List
Related Companies and Tools
